entertainment -WSS

entertainment

author：comprehensive 2025-08-26 23:47:25 - browse：764

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： California wildfire smoke linked to 52,000 early deaths, study says

leisure time

WSS

5 takeaways from STAT's examination of Zynex Medical

New report analyzes digital physical therapy solutions' effectiveness

Statins may not be needed by millions of people, study suggests

Covid's long

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

focus

entertainment

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Covid's long

Bright Health sells Medicare Advantage business to Molina

Cheap, fast test for Zika and dengue could cost just $1

Bright Health sells Medicare Advantage business to Molina

Target recalls 2.2 million additional candles due to laceration, burn hazards

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Teladoc has a new CEO, but challenges remain the same

Novavax promises a turnaround & Lilly roils the obesity market

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

hotspot

Newly revealed memo details efforts to keep Trump in power following election loss

Report captures long Covid’s disabling effects and policy challenges

Health care court cases: Humana, Sutter, Novant

Target recalls 2.2 million additional candles due to laceration, burn hazards

Cheap, fast test for Zika and dengue could cost just $1

Medical device trials still don't enroll enough women, study finds

leisure time

hotspot

leisure time

Wikipedia